×
Metagenomi Price to Free Cash Flow Ratio 2022-2024 | MGX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
Metagenomi price to free cash flow ratio from 2022 to 2024. Price to free cash flow ratio can be defined as
View More
Metagenomi Price to Free Cash Flow Ratio 2022-2024 | MGX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
Metagenomi price to free cash flow ratio from 2022 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$80.6B
Takeda Pharmaceutical (TAK)
$42.9B
Sandoz Group AG (SDZNY)
$19.7B
Merck (MKKGY)
$19.3B
Astellas Pharma (ALPMY)
$18.3B
United Therapeutics (UTHR)
$16.5B
Summit Therapeutics (SMMT)
$14.2B
Neurocrine Biosciences (NBIX)
$12.9B
Shionogi (SGIOY)
$12.2B
Catalent (CTLT)
$11.1B
Madrigal Pharmaceuticals (MDGL)
$7.5B
Orion OYJ (ORINY)
$6.7B
Corcept Therapeutics (CORT)
$6.2B
Ionis Pharmaceuticals (IONS)
$5.6B
Crinetics Pharmaceuticals (CRNX)
$5.2B
PTC Therapeutics (PTCT)
$3.3B
Dyne Therapeutics (DYN)
$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.5B
Soleno Therapeutics (SLNO)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2.3B
NewAmsterdam Pharma (NAMS)
$1.9B
Xencor (XNCR)
$1.8B
Evotec AG (EVO)
$1.7B
Recursion Pharmaceuticals (RXRX)
$1.7B
Guardian Pharmacy Services (GRDN)
$1.6B
BioCryst Pharmaceuticals (BCRX)
$1.5B
Indivior (INDV)
$1.5B
Harrow (HROW)
$1.5B
Ocular Therapeutix (OCUL)
$1.4B